Alembic Pharmaceuticals on Tuesday reported 30 per cent rise in consolidated net profit to ₹169.83 crore for the quarter ended December 31, 2018 mainly on account of robust sales in the US.
The company had posted a net profit of ₹ 130.60 crore in the year-ago period, Alembic Pharma said in a filing to BSE.
Consolidated revenue from operations stood at ₹1,018.15 crore in the reported quarter as against ₹ 840.02 crore in December quarter 2017.
“The growth in the quarter was attributed to a strong performance in the US and international business,” MD Pranav Amin said.
The company’s formulation as well as active pharmaceutical ingredient (API) facilities were successfully approved by USFDA during the quarter, he added.
The US business grew 42 per cent to ₹ 308 crore for the December quarter 2018 as against ₹ 218 crore in the year-ago period, it said.
Shares of Alembic Pharma closed at ₹587.80 per scrip on BSE, down 0.60 per cent from the previous close.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.